IIM
AVBP icon

INTECH Investment Management’s ArriVent BioPharma AVBP Stock Holding History

INTECH Investment Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Sell
9,567
-2,252
-19% -$66.5K ﹤0.01% 1531
2026
Q1 		$273K Buy
11,819
+812
+7% +$18.3K ﹤0.01% 1606
2025
Q4 		$221K Buy
+11,007
New +$229K ﹤0.01% 1931
2025
Q3 		– Sell
-13,461
Closed -$293K – 2533
2025
Q2 		$293K Sell
13,461
-4,608
-26% -$95.7K ﹤0.01% 1873
2025
Q1 		$334K Buy
18,069
+3,271
+22% +$80K ﹤0.01% 1822
2024
Q4 		$394K Buy
+14,798
New +$425K ﹤0.01% 1691

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

INTECH Investment Management's AVBP Position: Q2 2026 in Review

INTECH Investment Management reduced its ArriVent BioPharma (AVBP) stake by 19% in Q2 2026, selling an estimated $66.5K and leaving 9,567 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #1531.

INTECH Investment Management first reported a position in AVBP in Q4 2024 and has held it in 6 quarters since. The position peaked at $394K in Q4 2024. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • INTECH Investment Management held 9,567 shares of ArriVent BioPharma worth $332K as of Q2 2026.
  • INTECH Investment Management sold 2,252 ArriVent BioPharma shares in Q2 2026, an estimated $66.5K.
  • ArriVent BioPharma made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1531 holding.
  • INTECH Investment Management first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 6 quarters since.
  • INTECH Investment Management's ArriVent BioPharma position peaked at $394K in Q4 2024.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.